Fulcrum Lowers Xoma to 'Neutral'

Analyst Darren Mac thinks the current stock price fully reflects the eventual approval of Xoma's psoriasis drug Raptiva

Fulcrum downgraded Xoma (XOMA ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.